Sökning: id:"swepub:oai:DiVA.org:oru-70216" >
A Swedish nationwid...
A Swedish nationwide pharmaco-epidemiological and genetic study of the long-term safety and effectiveness of dimethyl fumarate (IMSE 5)
-
- Demirbüker, S. Safer (författare)
- Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
-
- Kågström, S. (författare)
- Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
-
- Fält, A. (författare)
- Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
-
visa fler...
-
- Berglund, A. (författare)
- Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
-
- Hillert, J. (författare)
- Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
-
- Nilsson, P. (författare)
- Department of Neurology, Lund University, Lund, Sweden
-
- Dahle, C. (författare)
- Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden
-
- Svenningsson, A. (författare)
- Department of Clinical Sciences, Danderyd Hospital, Stockholm, Sweden
-
- Lycke, J. (författare)
- Department of Clinical Neuroscience and Rehabilitation, University of Gothenburg, Gothenburg, Sweden
-
- Landtblom, A. -M (författare)
- Department of Neuroscience, Uppsala University, Uppsala, Sweden
-
- Burman, J. (författare)
- Department of Neuroscience, Uppsala University, Uppsala, Sweden
-
- Sundström, P. (författare)
- Department of Clinical Neuroscience, Umeå University, Umeå, Sweden
-
- Martin, C. (författare)
- Department of Clinical Sciences, Danderyd Hospital, Stockholm, Sweden
-
- Gunnarsson, Martin, 1973- (författare)
- Örebro universitet,Institutionen för medicinska vetenskaper,Department of Neurology
-
- Piehl, F. (författare)
- Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
-
- Olsson, T. (författare)
- Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
-
visa färre...
-
(creator_code:org_t)
- Sage Publications, 2018
- 2018
- Engelska.
-
Ingår i: Multiple Sclerosis Journal. - : Sage Publications. - 1352-4585 .- 1477-0970. ; 24:Suppl. 2, s. 701-702
- Relaterad länk:
-
https://urn.kb.se/re...
Abstract
Ämnesord
Stäng
- Background: Dimethyl fumarate (DMF) is an oral therapy for relapsing-remitting multiple sclerosis (RRMS), which has been included in the Swedish post-market surveillance study “Immunomodulation and Multiple Sclerosis Epidemiology 5” (IMSE 5) in order to monitor and determine the long-term safety and effectiveness in a real-world setting.Objectives: To follow-up the long-term safety and effectiveness of DMF in a real-world setting.Methods: MS patients are registered into the nationwide Swedish Neuro Registry (NeuroReg) in Sweden. The IMSE 5 study obtains descriptive data of adverse events (AEs), Extended Disability Status Scale (EDSS), Multiple Sclerosis Severity Scale (MSSS), Symbol Digit Modalities Test (SDMT), Multiple Sclerosis Impact Scale (MSIS-29), European Quality of Life - Five Dimensions Test (EQ-5D) and Visual Analog Scale (VAS) from NeuroReg. Drug survival was measured using the Kaplan-Meier curve and effectiveness measures were assessed using the Wilcoxon Signed Rank Test.Results: 2010 DMF-treated patients have been included in the IMSE 5 study between March 2014 and April 2018. 73 % were female and the mean age at treatment start was 40.6 years. The mean treatment duration was 22.3 months. 92 % of the patients had RRMS with 2 % missing data on MS phenotype. Most patients switched from interferon and glaimer acetat (41 %) and 24 % of the patients were treatment naïve (13 % were missing data on prior treatment). The overall one year drug survival was 74 % and 889 patients terminated their treatment at some point. Most patients (39 %) switched to rituximab (15 % have no new treatment registered). The most common reason for discontinuation was AEs (53 %) and lack of effect (29 %). 227 (11 %) patients have continued treatment for ≥36 months. In patients treated with DMF continuously for ≥24 months (n=918), significant improvements in mean values at 24 months of treatment compared to mean baseline values have been noted for EDSS (1.9 ± 1.6 to 1.6 ± 1.6, n=196); MSSS (2.5 ± 2.4 to 2.0 ± 2.0, n=145); SDMT (52.6 ± 11.0 to 53.8 ± 11.7, n=315); MSIS-29 Psychological Subscale (26.3 ± 22.8 to 21.8 ± 20.6, n=337); and EQ-5D (0.76 ± 0.23 to 0.81 ± 0.20, n=284).Conclusions: NeuroReg proves to function well as a post-marketing drug surveillance platform, providing data regarding drug effectiveness and AEs. A longer follow-up period is needed to assess the real-world effectiveness and safety of DMF.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Neurologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Neurology (hsv//eng)
Publikations- och innehållstyp
- vet (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Demirbüker, S. S ...
-
Kågström, S.
-
Fält, A.
-
Berglund, A.
-
Hillert, J.
-
Nilsson, P.
-
visa fler...
-
Dahle, C.
-
Svenningsson, A.
-
Lycke, J.
-
Landtblom, A. -M
-
Burman, J.
-
Sundström, P.
-
Martin, C.
-
Gunnarsson, Mart ...
-
Piehl, F.
-
Olsson, T.
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Neurologi
- Artiklar i publikationen
-
Multiple Scleros ...
- Av lärosätet
-
Örebro universitet